Moroccan industrial powerhouse Dislog Group is pushing deeper into the healthcare sector with a new strategic move. The company has signed a preliminary agreement to acquire a 70% stake in Afrobiomedic, a well-established firm that specializes in implantable cardiology devices.
Afrobiomedic was founded in 2009 by Dr. Driss Nasr, who has spent over two decades building expertise in interventional cardiology, structural heart procedures, and cardiac rhythm management. Under his leadership, the company has become a key player in Morocco, focusing on the import and distribution of high-end medical devices. Dr. Nasr will retain a 30% ownership stake and continue to lead the company, with plans to expand its reach beyond Morocco and into broader African markets.
This deal is part of Dislog’s wider strategy to grow through acquisitions and broaden its presence in the medical and pharmaceutical space. Already active in this area through subsidiaries like Megaflex, Steripharma, and Kosmopharm, Dislog covers the full spectrum—from pharmaceutical manufacturing to the distribution of medical equipment and dermo-cosmetic products.
Afrobiomedic will now become part of this diversified network, bolstering Dislog’s capabilities in a sector that’s experiencing significant growth. With exclusive distribution partnerships and ISO 13485 certification, Afrobiomedic has built strong relationships with private clinics, public hospitals, and specialized medical centers throughout the country.
The completion of the acquisition is still pending regulatory approval from Morocco’s Competition Council.
